The Life Sciences team advised argenx SE (Euronext & Nasdaq: ARGX) on its global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary shares in the form of ADSs. The gross proceeds from the global offering were approximately $1.15 billion (approximately €954.8 million).

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

The Goodwin team was led by Michael Bison, Marishka DeToy, Amanda Schwarzenbart, and Stephanie Barbanell, and included Garrett Gaughan, Duncan Greenhalgh, Olivia Uitto, Ettore Santucci, and Nathan Needle, with invaluable assistance from John Mei and Edwin O’Connor.

For more details, read the press release and articles in Yahoo Finance, Seeking Alpha, and GlobalCapital.